Novo Nordisk A/S: Novo Nordisk discontinues development of vatreptacog alfa following analysis of phase 3 results
2012-09-28 · Novo Nordisk A/S · original novonordisk.com ↗
Novo Nordisk today announced the decision to discontinue the development of vatreptacog alfa, a fast-acting recombinant factor VIIa analogue for haemophilia patients with inhibitors. The decision follows analysis of the data from the phase 3a trial adeptTM 2. On 9 August, Novo Nordisk announced that a few patients in the trial had developed anti-drug antibodies to vatreptacog alfa, one patient with a potentially neutralising effect. Media: Investors: Mike Rulis Kasper Roseeuw Poulsen Tel: (+45) 3079 3573 Tel: (+45) 4442 4303 [email protected] [email protected] Frank Daniel Mersebach Tel: (+45) 4442 0604 [email protected] Lars Borup Jacobsen Tel: (+45) 3075 3479 [email protected] In North America: Ken Inchausti Jannick Lindegaard Tel: (+1) 609 514 8316 Tel: (+1) 609 786 4575 [email protected] [email protected] Company Announcement No 60 / 2012
The release as fetched from its publisher. novonordisk.com ↗